OTCMKTS:PXSLY Pharmaxis (PXSLY) Stock Price, News & Analysis $0.88 0.00 (0.00%) As of 06/8/2021 Add Compare Share Share Stock Analysis Stock Analysis About Pharmaxis Stock (OTCMKTS:PXSLY) Get Pharmaxis alerts:Sign Up Key Stats Today's Range$0.88▼$0.8850-Day Range$0.88▼$0.8852-Week Range$0.62▼$1.47VolumeN/AAverage Volume1,000 shsMarket Capitalization$26.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pharmaxis Ltd. is an Australian biotechnology company focused on developing therapeutics for serious and chronic diseases. The company has historically concentrated on respiratory medicine and on research programs targeting fibrotic diseases and cancers. Pharmaxis developed Bronchitol, an inhaled dry-powder formulation of mannitol designed to help clear mucus from the lungs of people with cystic fibrosis. It also developed Aridol, a mannitol-based bronchial challenge test used to assess airway hyperresponsiveness and support the diagnosis of asthma. These products have been marketed in Australia and other international markets through regulatory approvals and commercial partnerships. In addition to its respiratory portfolio, Pharmaxis has pursued small-molecule drug candidates that inhibit lysyl oxidase enzymes. The company has investigated these programs in conditions involving tissue fibrosis and certain blood cancers, including myelofibrosis. Pharmaxis is based in Australia and has served international markets through its product registrations, distributors and licensing relationships.AI Generated. May Contain Errors. Read More Receive PXSLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXSLY Stock News HeadlinesSyntara Receives FDA Guidance on Amsulostat Development for MyelofibrosisAugust 10, 2025 | tipranks.comSyntara’s Amsulostat Receives WHO INN Recognition, Boosting Myelofibrosis Treatment ProspectsJuly 7, 2025 | tipranks.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 16 at 1:00 AM | Behind the Markets (Ad)Syntara’s SNT-5505 Receives FDA Fast Track Designation for Myelofibrosis TreatmentJune 9, 2025 | tipranks.comPharmaxis Ltd Highlights Uncertainties in Syntara’s Future ProjectionsMay 6, 2025 | tipranks.comPharmaxis Ltd March Quarter Shareholder UpdateApril 30, 2025 | tipranks.comSyntara’s SNT-6302 Shows Promising Results in Scar Treatment TrialFebruary 17, 2025 | tipranks.comPharmaxis Ltd General Meeting Addresses Key ResolutionsFebruary 16, 2025 | tipranks.comSee More Headlines PXSLY Stock Analysis - Frequently Asked Questions How have PXSLY shares performed this year? Pharmaxis' stock was trading at $0.88 at the beginning of 2026. Since then, PXSLY shares have increased by 0.0% and is now trading at $0.88. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:PXSLY CIK1301357 Webwww.pharmaxis.com.au Phone61-2-9454-7200FaxN/AEmployees69Year Founded1998Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.82 Current Ratio3.31 Quick Ratio2.92 Sales & Book Value Annual Sales$8.75 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book22.00Miscellaneous Outstanding Shares30,150,000Free FloatN/AMarket Cap$26.53 million OptionableNot Optionable Beta1.22 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:PXSLY) was last updated on 6/8/2021 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredThe oil check Munger called his best dealCharlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million ov...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
